Special Combination of OBP-301 and Pembrolizumab

NCT03172819 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Advanced Solid Tumor

Interventions

BIOLOGICAL: OBP-301
DRUG: Pembrolizumab

Sponsor

Toshihiko Doi

Collaborators

[object Object]
[object Object]